Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S, Grinyó J, Mamode N, Rigotti P, Couzi L, Büchler M, Sandrini S, Dain B, Garfield M, Ogawa M, Richard T, Marks WH; C10-002 Study Group. Glotz D, et al. Among authors: tufveson g. Am J Transplant. 2019 Oct;19(10):2865-2875. doi: 10.1111/ajt.15397. Epub 2019 May 24. Am J Transplant. 2019. PMID: 31012541 Free PMC article. Clinical Trial.
Is rituximab safe to use in kidney transplant patients?
Tydén G, Mjornstedt L, Ekberg H, Tufveson G. Tydén G, et al. Among authors: tufveson g. Am J Transplant. 2010 Aug;10(8):1949; author reply 1950. doi: 10.1111/j.1600-6143.2010.03145.x. Am J Transplant. 2010. PMID: 20659100 Free article. Clinical Trial. No abstract available.
An ABO incompatible sibling as rescue kidney donor.
Blohmé I, Mjörnstedt L, Rydberg L, Nyberg G, Tufveson G. Blohmé I, et al. Among authors: tufveson g. Transplant Proc. 1994 Jun;26(3):1745. Transplant Proc. 1994. PMID: 8030115 No abstract available.
Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients.
Lorant T, Bengtsson M, Eich T, Eriksson BM, Winstedt L, Järnum S, Stenberg Y, Robertson AK, Mosén K, Björck L, Bäckman L, Larsson E, Wood K, Tufveson G, Kjellman C. Lorant T, et al. Among authors: tufveson g. Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733. Epub 2018 Apr 17. Am J Transplant. 2018. PMID: 29561066 Free PMC article. Clinical Trial.
Low 1-year cyclosporine microemulsion doses are associated with better 5-year renal graft function: an insight from MOST, a multinational observational study.
Salvadori M, Rosati A, Bertoni E, Bock A, Chapman J, Dussol B, Fritsche L, Kliem V, Lebranchu Y, Oppenheimer F, Pohanka E, Tufveson G, Soergel M. Salvadori M, et al. Among authors: tufveson g. Transplant Proc. 2006 May;38(4):1010-3. doi: 10.1016/j.transproceed.2006.03.060. Transplant Proc. 2006. PMID: 16757247
Is kidney transplantation in sensitized recipients justified?
Bersztel A, Wadström J, Tufveson G, Gannedahl G, Bengtsson M, Bergström C, Frödin L, Claesson K, Wikström B, Wahlberg J. Bersztel A, et al. Among authors: tufveson g. Transpl Int. 1996;9 Suppl 1:S49-53. doi: 10.1007/978-3-662-00818-8_14. Transpl Int. 1996. PMID: 8959790
282 results